Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma in adults. Although 60–70% of patients achieve remission with first-line immunochemotherapy (R-CHOP or pola-R-CHP), approximately 30%-40% of patients still experience develop refractory or relapsed disease. Treatment resistance still remains as the major challenge in DLBCL patient management. Although there is no significant synergy among the components in the R-CHOP or Pola-R-CHP regimens, cross-resistance be